Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma

Annals of Oncology

Volumn 19, Issue 6, 2008, Pages 1160-1165

  Palumbo, A ^a   Gay, F ^a   Bringhen, S ^a   Falcone, A ^b   Pescosta, N ^c   Callea, V ^d   Caravita, T ^e   Morabito, F ^f   Magarotto, V ^a   Ruggeri, M ^a   Avonto, I ^a   Musto, P ^g   Cascavilla, N ^b   Bruno, B ^a   Boccadoro, M ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c Ospedale Centrale   (Italy)

^d BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f Azienda Ospedaliera di Cosenza   (Italy)

^g REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

Bortezomib; Myeloma; Relapse

Indexed keywords

ACICLOVIR; ANTHRACYCLINE; BORTEZOMIB; CIPROFLOXACIN; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE;

ACUTE HEART FAILURE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER RELAPSE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEART DISEASE; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; SALVAGE THERAPY; SENSORY NEUROPATHY; THROMBOCYTOPENIA; THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; SALVAGE THERAPY;

EID: 44849092180     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn018     Document Type: Article

References (32)

1. Boyle P, Feday J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-488.
2. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
3. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
4. Adams J. The proteasome: A suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349-360.
5. Mitsiades N, Mitsiades CS, Richardson PG et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 2003; 101: 2377-2380.
6. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
7. Jagannath S, Barlogie B, Berenson J et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165-172.
8. Niesvizky R, Richardson PG, Sonneveld P et al. Relationship between quality of response to Bortezomib (btz) and clinical benefit in multiple myeloma (MM) in the APEX and SUMMIT studies, Blood 2006; 108: 1007a (Abstr 3529).
9. Orlowski RZ, Voorhees PM, Garcia RA et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058-3065.
10. Orlowski RZ, Zhuang SH, Parekh T et al. The combination of pegylated liposomal doxorubicin and Bortezomib significantly improves time to progression of patients with relapse/refractory multiple myeloma compared with Bortezomib alone: Results from a planned interim analisys of a randomized phase III study. Blood 2006; 108: 124a (Abstr 404).
11. Oakervee HE, Popat R, Curry N et al. PAD combination therapy (PS-341/ Bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755-762.
12. Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
13. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842-854.
14. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS 2006. http://ctep.cancer.gov.
15. Ahmann GJ, Jalal SM, Juneau AL et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gamopathies. Cancer Genet Cytogenet 1998; 101: 7-11.
16. Fonseca R, Barlogie B, Batalle R et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 2004; 64: 1546-1558.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
18. Jagannath S, Richardson PG, Barlogie B et al. for the SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006; 91: 929-934.
19. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
20. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
21. Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
22. Rajkumar SV, Dispenzieri A. Evaluation and monitoring of response to therapy in multiple myeloma. Haematologica 2005; 90: 1305-1308.
23. Palumbo A, Bringhen S, Falco P et al. Time to first progression, but not β2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer 2007; 110: 824-829.
24. Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289-3294.
25. Richardson PG, Barlogie B, Berenson J et al. Clinical factors predictive of outcome with bortezomb in patents with relapsed, refractory multiple myeloma. Blood 2005; 106: 2977-2981.
26. Mateos MV, Hernandez JM, Hernandez MT et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006; 108: 2165-2172.
27. Jagannath S, Richardson PG, Sonneveld P et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007; 21: 151-157.
28. Sagaster V, Ludwig H, Kaufmann H et al. Bortezomib in relapsed multiple myeloma: Response rates and duration of response are indipendent of a chromosome 13q-deletion. Leukemia 2007; 21: 164-168.
29. Palumbo A, Ambrosini MT, Benevolo G et al. Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood 2007; 109: 2767-2772.
30. Berenson JR, Yang HH, Sadler K et al, Phase I/II trial assesing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24: 937-944.
31. Offidani M, Corvatta L, Marconi M et al. Low-dose talidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/ refractory multiple myeloma: A prospective, multicenter, phase II. Haematologica 2006; 91: 133-136.
32. Zangari M, Siegel E, Barlogie B et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy. Blood 2002; 100: 1168-1171.